GastroLab

WDHD2026
Chronic diarrhea demands better diagnosis, not more trials.
May 29 marks World Digestive Health Day and throughout this month of May we’ll be focusing on chronic diarrhea; its hidden drivers, and how at GastroLab we are closing the diagnostic gap through innovations and tests that are aligned to demographic and epidemiological needs of India. More insights coming soon.

WORLD DIGESTIVE HEALTH DAY 2026
Chronic diarrhea is often approached as a label rather than a mechanism.

But inflammation, malabsorption, bile acid dysfunction, motility disorders, microbiome alterations, and gut-brain dysregulation can all produce similar symptom patterns.

The challenge is not simply treating diarrhea BUT TO IDENTIFY the dominant physiological pathway driving it.

And a mechanism based approach may change both diagnostics and therapy.

WATCH THIS SPACE FOR MORE as we approach the world digestive disease day 2026 the theme for which is chronic diarrhea we attempt to identify diagnostic gaps thoughout this month.

Come join us to spread the message…

(CRC) is rising at an alarming rate in India, now ranking as the country's fourth most common cancer.

Colon Cancer demographics are shifting in India with up to 40% of patients now under the age of 40. In such settings routine early screening is critical.

But are we using the most effective tests?

Standard FIT testing has a biological blind spot: Hemoglobin degrades during colonic transit, which often leads to missed right-sided (proximal) tumors.

The ColonView Dual Biomarker FIT

It detects both Human Hemoglobin (Hb) AND the highly stable Hb/Hp Complex.
ColonView resists degradation and captures the signals that standard FIT misses.

📊 The Clinical Advantage:

✅ 100% detection of proximal neoplasia & carcinoma in study cohorts

✅ No dietary restrictions (significantly better patient compliance)

✅ 15-minute rapid results from a single sample

Screening isn't just about detecting blood; it's about detecting the right biological signal. It's time to eliminate diagnostic blind spots.

📩 Reach out to [email protected] to integrate ColonView into your clinical practice or Labs today.

🚨Attention please🚨

Fresh off the press!

A game changing study done at AIIMS under the guidance of Dr. Govind K. Makharia on chronic diarrhea and Bile Acid Malabsorption (BAM) has just been published in the Indian Journal of Gastroenterology and we at GastroLab India Pvt. Ltd are proud to have supported this incredibly important study.

"Could a single spot stool sample be the key to unlocking the hidden cause of chronic diarrhea for millions of patients?"

For years, diagnosing BAM has been a major clinical challenge. The gold standard test (75SeHCAT) is costly, requires radiation, and isn't widely available outside Europe. As a result, BAM is often missed in patients with chronic diarrhea.

But what if a single stool sample could change that?

This pilot observational study evaluated the IDK® Bile Acid test, a simple enzymatic spectrophotometric assay to measure total stool bile acids in a single spot sample.

Here are the steaming hot findings:

✅ High Accuracy:

An optimal f***l bile acid (FBA) cut-off of 2.8 µmol/g yielded 89.5% sensitivity and 92.0% specificity.

✅ High Prevalence Discovered:

BAM was identified in:

• 88.1% of patients with ileal 's disease

• 57.0% of post- patients

• 54.5% of patients

• 21.0% of -D and functional patients

The authors concluded that

“single spot FBA estimation……… may be a promising tool for diagnosing BAM in patients with chronic diarrhea, especially in low-resource settings….. Increasing use
of spot FBA may help diagnose more patients with BAM and
improve management of chronic diarrhea considerably. “

We finally have a promising, simple, and accessible diagnostic tool for BAM. This could help avoid inappropriate treatment and offer targeted relief for patients suffering from chronic diarrhea.

At GastroLab India Pvt. Ltd , we are committed to closing diagnostic gaps in Indian healthcare through state of the art, epidemiologically relevant testing solutions.

Share ♻️ this pathbreaking research

Link to article 👇🏽👇🏽

Mehta, S., Agarwal, S., Pachisia, A.V. et al. A single test strategy using spot f***l bile acid test may be a feasible strategy for the diagnosis of bile acid malabsorption. Indian J Gastroenterol (2026).

https://doi.org/10.1007/s12664-026-01972-y

A single test strategy using spot f***l bile acid test may be a feasible strategy for the diagnosis of bile acid malabsorption - Indian Journal of Gastroenterology Background Bile acid malabsorption (BAM) is often missed in patients with chronic diarrhea as diagnostic tests are technically challenging and not available widely. Quantitative estimation of f***l bile acids (FBA) in a single stool sample has been reported recently for the diagnosis of BAM and may....

Stop guessing and start testing because when it comes to Lactose Intolerance, "non-invasive" doesn't always mean "accurate."

The standard Lactose Breath Test (LBT) is widely used, but it carries a hidden risk: a 20% false-negative rate. That means 1 in 5 patients might be told they are fine, while they continue to suffer from undiagnosed lactase deficiency.

Our latest infographic breaks down why the Lactose Intolerance Quick Test (LIQT); a 20-minute biopsy based assay is becoming the essential gold standard for clinicians who prioritize diagnostic stewardship.

Why LIQT outperforms LBT:

• Sensitivity: LQT hits 100% sensitivity, compared to just 76.5% for the breath test.

• Speed: No more 4-hour breath sampling. Get semi-quantitative results in just 20 minutes during the endoscopic procedure.

• Predictive Power: With a 98% predictive success rate, LQT accurately identifies which patients will actually see clinical improvement on a lactose-free diet.

• No Methane Interference: Unlike LBT, isn't fooled by methane-producing bacteria that can skew hydrogen readings.

Are you still relying on tests, or are you ready for 100% diagnostic certainty?

📍 GastroLab India Pvt. Ltd Pune

📧 [email protected]

📞 +91 88893 99915

Furnari M, Bonfanti D, Parodi A, et al. A comparison between lactose breath test and quick test on duodenal biopsies for diagnosing lactase deficiency in patients with self-reported lactose intolerance. J Clin Gastroenterol. 2013;47(2):148-152. doi:10.1097/MCG.0b013e31824e9132



Healthy Gut Initiative

Colon Cancer Screeinng : Are we detecting the right signal?

Standard stool tests have a biological spot. While standard Immunochemical FIT was a significant upgrade from traditional Guaiac (gFOBT) tests, it relies solely on detecting hemoglobin (Hb). Because hemoglobin degrades during colonic transit, standard FIT often struggles to detect (proximal) lesions.

To detect earlier, we have to detect smarter.

Biomarker represents the next evolution in stool testing. By detecting both Hb and the highly stable Hemoglobin-Haptoglobin (Hb/Hp) complex, we can overcome transit degradation and achieve comprehensive coverage of the entire colon.

Performance Highlights:

• 97.3% Sensitivity & 85.1% Specificity

• AUC 0.912 (Compared to 0.87 for standard FIT and 0.77 for gFOBT)

• 100% detection of proximal tumors in the study cohort which is completely missed by FOBTs and single biomarker FITs

Advantages for Clinics & Labs:

• Reliably detects bleeding from both proximal and distal colon

• Requires only one sample for dual testing

• Delivers rapid results in 15 minutes

• Zero dietary restrictions for the patient

Colon cancer screening isn't just about detecting blood; it's about identifying the right biological signal to catch lesions in their silent phase.

Let's elevate our diagnostic standards this March.
Reach out to the team at [email protected] to learn how to implement smarter screening protocols in your practice.